Enzyme Research
Studies from University of Sheffield further understanding of enzyme research
Published in Clinical Oncology Week, July 20th, 2009
"The therapeutic potential of combining the prototype tumor vascular-disrupting agent combretastatin A-4 3-O phosphate (CA-4-P) with systemic nitric oxide synthase (NOS) inhibition was; investigated preclinically. Vascular response (uptake of I-125-labeled iodoantipyrine; laser Doppler flowmetry) and tumor response (histologic necrosis; cytotoxicity and growth delay) were determined," researchers in Sheffield, the United Kingdom report.
"Inducible NOS selective inhibitors had no effect on blood flow in the P22 rat sarcoma. In contrast, the non-isoform-specific NOS inhibitor N-omega-nitro-L-arginine (L-NNA; 1 and 10 mg/kg i.v. or chronic 0.1 or 0.3 mg/mL in drinking...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- American Association for Cancer Research
2 reproductive factors are important predictors of death from ovarian cancer - Boston University Medical Center
Study shows endoscopic surgery as effective open surgery for nasal cancer - Burnham Institute
Carbohydrate acts as tumor suppressor - Columbia University Medical Center
Genetic factors implicated in survival gap for breast, ovarian or prostate cancer - Columbia University's Mailman School of Public Health
Elderly breast cancer patients receive chemotherapy if treated in private practices - Fred Hutchinson Cancer Research Center
Link between migraines and reduced breast cancer risk confirmed in follow-up study - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
